Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled, Double-blind, Six-way Crossover, Single-dose Exposure Study to Compare the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™100/10μg and 250/10μg) in a Single Inhaler (SkyePharma HFA MDI) With the Administration of Fluticasone (250μg) and Formoterol (12μg) Concurrently or Alone in Patients With Asthma
Conditions
Interventions
fluticasone propionate, formoterol fumarate
fluticasone propionate, formoterol fumarate
+4 more
Locations
6
Ireland
Investigational site
Belfast, Ireland
Investigational site
Derbyshire, United Kingdom
Investigational site
London, United Kingdom
Investigational site
Manchester, United Kingdom
Investigational site
Plymouth, United Kingdom
Investigational site
Slough, United Kingdom
Start Date
October 1, 2004
Primary Completion Date
January 1, 2005
Completion Date
January 1, 2005
Last Updated
June 23, 2011
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
SkyePharma AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions